CALT:NSD-Calliditas Therapeutics (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 20.78

Change

-1.55 (-6.93)%

Market Cap

USD 0.65B

Volume

1.60K

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

CALT Stock Forecast & Price:
Based on the Calliditas Therapeutics stock forecasts from 2 analysts, the average analyst target price for Calliditas Therapeutics is USD 0.00 over the next 12 months. Calliditas Therapeutics’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Calliditas Therapeutics is Bearish, which is based on 2 positive signals and 7 negative signals. At the last closing, Calliditas Therapeutics’s stock price was USD 20.78. Calliditas Therapeutics’s stock price has changed by +1.61% over the past week, +21.81% over the past month and -29.56% over the last year.

About Calliditas Therapeutics (CALT:NSD)

Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formul ...Read More

Company Website : https://www.calliditas.se

Address : Kungsbron 1, D5, Stockholm, Sweden, 111 22

Employees : 71

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 1.39

52 Week High : 32.92

Short Ratio : 1.74

52 Week Low : 12.55

Shorted Shares : 7,466

200 Day Moving Average : 18.95

Shorted Shares Previous Month : 9,693

50 Day Moving Average : 18.40

Short Percentage : 0.27%

Shares Held by Institutions : 3.39%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-08-09 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Inc

+4.88 (+1.66%)

 USD73.74B 29.01 20.60
MRNA Moderna Inc

-11.80 (-6.45%)

 USD71.57B 5.79 4.08
REGN Regeneron Pharmaceuticals Inc

-8.48 (-1.34%)

 USD68.73B 12.65 9.34
BNTX BioNTech SE

-12.09 (-7.14%)

 USD40.37B 3.26 2.01
ALXN Alexion Pharmaceuticals Inc

N/A

 USD40.34B 59.23 42.56
SGEN Seagen Inc

-2.73 (-1.53%)

 USD32.89B 55.02 -46.79
RPRX Royalty Pharma Plc

+0.54 (+1.25%)

 USD28.69B 41.21 16.21
ALNY Alnylam Pharmaceuticals Inc

-7.37 (-3.19%)

 USD27.46B N/A -34.32
GMAB Genmab AS

-0.08 (-0.23%)

 USD22.96B 73.23 6.37
BGNE BeiGene Ltd

-4.62 (-2.28%)

 USD21.09B N/A -7.47

ETFs Containing CALT

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -16.07% 73% C 52% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -16.07% 73% C 51% F
Trailing 12 Months  
Capital Gain -34.41% 70% C- 41% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -34.41% 70% C- 40% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -10.09% 38% F 21% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -10.09% 38% F 21% F
Risk Return Profile  
Volatility (Standard Deviation) 23.83% 94% A 65% D
Risk Adjusted Return -42.36% 28% F 23% F
Market Capitalization 0.65B 75% C 63% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio -99,999.99 88% B+ 99% A+
Price/Book Ratio 7.46 13% F 12% F
Price / Cash Flow Ratio -1.41 33% F 58% F
EV/EBITDA -1.12 53% F 65% D
Management Effectiveness  
Return on Equity -58.28% 50% F 21% F
Return on Invested Capital -43.24% 61% D- 23% F
Return on Assets -26.36% 49% F 16% F
Debt to Equity Ratio 18.76% 53% F 62% D-
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 1.74 69% D+ 66% D
Short Percent 0.27% 94% A 86% B
Beta 1.39 43% F 30% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date
New Post

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector